OpenBit ResearchOpenBit
中文

What's driving Regeneron Pharmaceuticals (REGN)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Pasatru FOPI Commercialization Durability

Why it matters now

Durable adoption of an approved monthly Pasatru treatment could create recurring REGN revenue through treatment of adults with fibrodysplasia ossificans progressiva.

Next checkpoint

REGN earnings (expected 2026-10-30)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to REGN, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Approved dosing is not tolerated and the lower dosage option fails to preserve continued treatment, or administration does not translate into recurring use.

Research drivers

  • Pasatru FOPI Commercialization Durability

    Bullish · Active · Updated

    Pasatru has an approved FOPI indication and administration flexibility that support adoption, with tolerability-dependent dosing as the key uncertainty.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • The U.S. Food and Drug Administration approved Regeneron's Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva.

    Relayed by: Benzinga · Event date on record:

  • In the Phase 3 OPTIMA trial, the 10 mg/kg dose decreased clinician-assessed flare-ups by 88%.

    Relayed by: Benzinga · Event date on record:

  • The European Medicines Agency is currently reviewing the treatment.

    Relayed by: Benzinga · Event date on record:

  • Regeneron plans additional regulatory applications worldwide, including in Japan.

    Relayed by: Benzinga · Event date on record:

  • Pasatru is a fully human monoclonal antibody that blocks Activin A, the protein responsible for developing the abnormal bone lesions.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.